Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
Menu

Contact Us
If you have any questions or feedback please contact us.
 Back to Details

Connection

Leigh Perreault to Hypoglycemic Agents

This is a "connection" page, showing publications Leigh Perreault has written about Hypoglycemic Agents.

 
Connection Strength
  
 
 
3.107
  
  1. Perreault L, Bergman BC. Out of stock: A brief clinical reference for rough equivalency of glucagon-like peptide-1 (GLP-1) ± glucose-dependent insulinotropic polypeptide (GIP) receptor agonists for A1c and weight reduction in people with type 2 diabetes. J Diabetes. 2024 Jun; 16(6):e13505.
    View in: PubMed
    Score: 0.447
  2. Perreault L, Skyler JS, Rosenstock J. Novel therapies with precision mechanisms for type 2 diabetes mellitus. Nat Rev Endocrinol. 2021 06; 17(6):364-377.
    View in: PubMed
    Score: 0.374
  3. Perreault L, Vincent L, Neumiller JJ, Santos-Cavaiola T. Initiation and Titration of Basal Insulin in Primary Care: Barriers and Practical Solutions. J Am Board Fam Med. 2019 May-Jun; 32(3):431-447.
    View in: PubMed
    Score: 0.326
  4. Perreault L, Rodbard H, Valentine V, Johnson E. Optimizing Fixed-Ratio Combination Therapy in Type 2 Diabetes. Adv Ther. 2019 02; 36(2):265-277.
    View in: PubMed
    Score: 0.319
  5. Perreault L. EMPA-REG OUTCOME: The Endocrinologist's Point of View. Am J Med. 2017 Jun; 130(6S):S51-S56.
    View in: PubMed
    Score: 0.285
  6. Perreault L. EMPA-REG OUTCOME: The Endocrinologist's Point of View. Am J Cardiol. 2017 07 01; 120(1S):S48-S52.
    View in: PubMed
    Score: 0.284
  7. Perreault L, Temprosa M, Mather KJ, Horton E, Kitabchi A, Larkin M, Montez MG, Thayer D, Orchard TJ, Hamman RF, Goldberg RB. Regression from prediabetes to normal glucose regulation is associated with reduction in cardiovascular risk: results from the Diabetes Prevention Program outcomes study. Diabetes Care. 2014 Sep; 37(9):2622-31.
    View in: PubMed
    Score: 0.233
  8. Perreault L, Pan Q, Mather KJ, Watson KE, Hamman RF, Kahn SE. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet. 2012 Jun 16; 379(9833):2243-51.
    View in: PubMed
    Score: 0.202
  9. Perreault L, Davies M, Frias JP, Laursen PN, Lingvay I, Machineni S, Varbo A, Wilding JPH, Wallenstein SOR, le Roux CW. Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program. Diabetes Care. 2022 10 01; 45(10):2396-2405.
    View in: PubMed
    Score: 0.103
  10. Goldberg RB, Tripputi MT, Boyko EJ, Budoff M, Chen ZZ, Clark JM, Dabelea DM, Edelstein SL, Gerszten RE, Horton E, Mather KJ, Perreault L, Temprosa M, Wallia A, Watson K, Irfan Z. Hepatic Fat in Participants With and Without Incident Diabetes in the Diabetes Prevention Program Outcome Study. J Clin Endocrinol Metab. 2021 10 21; 106(11):e4746-e4765.
    View in: PubMed
    Score: 0.097
  11. Goldberg RB, Bray GA, Marcovina SM, Mather KJ, Orchard TJ, Perreault L, Temprosa M. Non-traditional biomarkers and incident diabetes in the Diabetes Prevention Program: comparative effects of lifestyle and metformin interventions. Diabetologia. 2019 01; 62(1):58-69.
    View in: PubMed
    Score: 0.078
  12. Hivert MF, Christophi CA, Franks PW, Jablonski KA, Ehrmann DA, Kahn SE, Horton ES, Pollin TI, Mather KJ, Perreault L, Barrett-Connor E, Knowler WC, Florez JC. Lifestyle and Metformin Ameliorate Insulin Sensitivity Independently of the Genetic Burden of Established Insulin Resistance Variants in Diabetes Prevention Program Participants. Diabetes. 2016 Feb; 65(2):520-6.
    View in: PubMed
    Score: 0.064
  13. Kim C, Edelstein SL, Crandall JP, Dabelea D, Kitabchi AE, Hamman RF, Montez MG, Perreault L, Foulkes MA, Barrett-Connor E. Menopause and risk of diabetes in the Diabetes Prevention Program. Menopause. 2011 Aug; 18(8):857-68.
    View in: PubMed
    Score: 0.048
  14. Crandall JP, Polsky S, Howard AA, Perreault L, Bray GA, Barrett-Connor E, Brown-Friday J, Whittington T, Foo S, Ma Y, Edelstein SL. Alcohol consumption and diabetes risk in the Diabetes Prevention Program. Am J Clin Nutr. 2009 Sep; 90(3):595-601.
    View in: PubMed
    Score: 0.041
  15. Perreault L, Kahn SE, Christophi CA, Knowler WC, Hamman RF. Regression from pre-diabetes to normal glucose regulation in the diabetes prevention program. Diabetes Care. 2009 Sep; 32(9):1583-8.
    View in: PubMed
    Score: 0.041
  16. Perreault L, Ma Y, Dagogo-Jack S, Horton E, Marrero D, Crandall J, Barrett-Connor E. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care. 2008 Jul; 31(7):1416-21.
    View in: PubMed
    Score: 0.038
  17. Mottl AK, Alicic R, Argyropoulos C, Brosius FC, Mauer M, Molitch M, Nelson RG, Perreault L, Nicholas SB. KDOQI US Commentary on the KDIGO 2020 Clinical Practice Guideline for Diabetes Management in CKD. Am J Kidney Dis. 2022 04; 79(4):457-479.
    View in: PubMed
    Score: 0.025
  18. Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021 03 13; 397(10278):971-984.
    View in: PubMed
    Score: 0.023
  19. Herman WH, Pan Q, Edelstein SL, Mather KJ, Perreault L, Barrett-Connor E, Dabelea DM, Horton E, Kahn SE, Knowler WC, Lorenzo C, Pi-Sunyer X, Venditti E, Ye W. Impact of Lifestyle and Metformin Interventions on the Risk of Progression to Diabetes and Regression to Normal Glucose Regulation in Overweight or Obese People With Impaired Glucose Regulation. Diabetes Care. 2017 12; 40(12):1668-1677.
    View in: PubMed
    Score: 0.018
  20. Aroda VR, Knowler WC, Crandall JP, Perreault L, Edelstein SL, Jeffries SL, Molitch ME, Pi-Sunyer X, Darwin C, Heckman-Stoddard BM, Temprosa M, Kahn SE, Nathan DM. Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. Diabetologia. 2017 09; 60(9):1601-1611.
    View in: PubMed
    Score: 0.018
  21. Goldberg RB, Temprosa M, Mele L, Orchard T, Mather K, Bray G, Horton E, Kitabchi A, Krakoff J, Marcovina S, Perreault L, White N. Change in adiponectin explains most of the change in HDL particles induced by lifestyle intervention but not metformin treatment in the Diabetes Prevention Program. Metabolism. 2016 May; 65(5):764-775.
    View in: PubMed
    Score: 0.016
  22. Kim C, Christophi CA, Goldberg RB, Perreault L, Dabelea D, Marcovina SM, Pi-Sunyer X, Barrett-Connor E. Adiponectin, C-reactive protein, fibrinogen and tissue plasminogen activator antigen levels among glucose-intolerant women with and without histories of gestational diabetes. Diabet Med. 2016 Jan; 33(1):32-8.
    View in: PubMed
    Score: 0.016
  23. Hivert MF, Jablonski KA, Perreault L, Saxena R, McAteer JB, Franks PW, Hamman RF, Kahn SE, Haffner S, Meigs JB, Altshuler D, Knowler WC, Florez JC. Updated genetic score based on 34 confirmed type 2 diabetes Loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program. Diabetes. 2011 Apr; 60(4):1340-8.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)